PNC Financial Services Group’s INmune Bio INMB Stock Holding History

PNC Financial Services Group’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$82.6K	Sell	42,362 -276	-0.6%	-$568	﹤0.01%	3082
2026 Q2	$69.5K	Buy	42,638 +2,518	+6%	+$3.48K	﹤0.01%	3147
2026 Q1	$45.3K	Buy	40,120 +2,315	+6%	+$3.3K	﹤0.01%	3270
2025 Q4	$59K	Sell	37,805 -582	-2%	-$1.04K	﹤0.01%	3117
2025 Q3	$79.5K	Buy	38,387 +672	+2%	+$1.54K	﹤0.01%	2952
2025 Q2	$87.1K	Buy	+37,715	New	+$277K	﹤0.01%	2802
2022 Q3	–	Sell	-820	Closed	-$8K	–	4528
2022 Q2	$8K	Buy	+820	New	+$6.1K	﹤0.01%	3876

Other funds holding INMB

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Westside Investment Management Santa Monica, California $785M AUM 29.89% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Focus Partners Advisor Solutions Saint Louis, Missouri $12.4B AUM 18.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

PNC Financial Services Group's INMB Position: Q3 2026 in Review

PNC Financial Services Group reduced its INmune Bio (INMB) stake by 0.65% in Q3 2026, selling an estimated $568 and leaving 42,362 shares worth $82.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3082.

PNC Financial Services Group first reported a position in INMB in Q2 2022 and has held it in 7 quarters since. The position peaked at $87.1K in Q2 2025. 26 funds tracked by Wall St. Rank hold INMB as of Q3 2026.

PNC Financial Services Group held 42,362 shares of INmune Bio worth $82.6K as of Q3 2026.
PNC Financial Services Group sold 276 INmune Bio shares in Q3 2026, an estimated $568.
INmune Bio made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #3082 holding.
PNC Financial Services Group first reported a position in INmune Bio in Q2 2022 and has held it in 7 quarters since.
PNC Financial Services Group's INmune Bio position peaked at $87.1K in Q2 2025.
26 funds tracked by Wall St. Rank held INmune Bio as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.